Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 5/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.52 |
| ▸ | DRD1 | P21728 | 2/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.52 |
| ▸ | HTR7 | P34969 | 2/20 | 0.52 |
| ▸ | HRH1 | P35367 | 2/20 | 0.52 |
| ▸ | DRD3 | P35462 | 2/20 | 0.52 |
| ▸ | HTR2B | P41595 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.52 |
| ▸ | MLNR | O43193 | 1/20 | 0.52 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.52 |
| ▸ | HTR3B | O95264 | 1/20 | 0.52 |
| ▸ | HMGCR | P04035 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8865738 | 0.90 | KCNH2 (0.52) | HTR4KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8865630 | 0.90 | HTR4 (0.52) | HTR4KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8866229 | 0.90 | HTR4 (0.64) | HTR4KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8866468 | 0.87 | KCNH2 (0.48) | HTR4KCNH2CYP3A4CYP2D6CYP2C9 | |
| Water SCHEMBL7130515 | 0.86 | KCNH2 (0.49) | HTR4KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8417804 | 0.84 | DRD3 (0.50) | KCNH2CYP2D6HTR1ADRD2DRD1 | |
| SCHEMBL8416209 | 0.83 | KCNH2 (0.45) | HTR4KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8417837 | 0.83 | KCNH2 (0.45) | HTR4KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL22462315 | 0.80 | HTR4 (0.44) | HTR4KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8866360 | 0.79 | HTR4 (0.51) | HTR4KCNH2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313030-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | Terran Biosciences, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2022212854-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2022-10-06 | — | — | WO | claimed |
| US-12612364-B2 | Salts and solid forms of 4-hydroxy-N,N-diisopropyltryptamine hemi-glutarate and hemi-succinate | TERRAN BIOSCIENCES INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260085041-A1 | SALTS AND SOLID FORMS OF 4-HYDROXY-N,N-DIISOPROPYLTRYPTAMINE HEMI-GLUTARATE AND HEMI-SUCCINATE | TERRAN BIOSCIENCES INC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4429672-A1 | PSILOCYBIN AND O-ACETYLPSILOCIN, SALTS AND SOLID STATE FORMS THEREOF | Terran Biosciences Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| EP-4387608-A1 | PRODRUGS AND DERIVATIVES OF PSILOCIN AND USES THEREOF | Terran Biosciences, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20240165079-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2024-05-23 | — | — | US | disclosed |
| EP-4313030-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | Terran Biosciences, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023235766-A2 | METHODS FOR ACQUIRING AND ANALYZING NEUROMELANIN-SENSITIVE MRI | UNIVERSITY OF OTTAWA INSTITUTE OF MENTAL HEALTH RESEARCH (CA) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023141595-A2 | FUNCTIONALIZED ALKYLAMINES | TERRAN BIOSCIENCES, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023115002-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023107931-A1 | SALT AND SOLID FORMS OF INDOLE ANALOGS AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023108172-A2 | ANALOGS OF 4-SUBSTITUTED-2,5-DIMETHOXYAMPHETAMINE | TERRAN BIOSCIENCES, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023086962-A1 | PSILOCYBIN AND O-ACETYLPSILOCIN, SALTS AND SOLID STATE FORMS THEREOF | TERRAN BIOSCIENCES INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023081897-A1 | ISOTOPICALLY ENRICHED 3,4-METHYLENEDIOXY-N-ETHYLAMPHETAMINE (MDE) AND STEREOISOMERS THEREOF | TERRAN BIOSCIENCES, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081899-A1 | ISOTOPICALLY ENRICHED N-METHYL-1,3-BENZODIOXOLYLBUTANAMINE (MBDB) AND STEREOISOMERS THEREOF | TERRAN BIOSCIENCES, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081895-A1 | ISOTOPICALLY ENRICHED ANALOGS OF 5,6-METHYLENEDIOXY-2-AMINOINDANE (MDAI) | TERRAN BIOSCIENCES, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081892-A1 | ANALOGS OF N,N,N-TRIMETHYL-4-PHOSPHORYLOXYTRYPTAMINE | TERRAN BIOSCIENCES, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023023347-A1 | PRODRUGS AND DERIVATIVES OF PSILOCIN AND USES THEREOF | TERRAN BIOSCIENCES INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2022212854-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612364-B2 | Salts and solid forms of 4-hydroxy-N,N-diisopropyltryptamine hemi-glutarate and hemi-succinate | SLC6A4, DLST, GRIN2D | HTR4 74/4885KCNH2 880/4885CYP3A4 858/4885 |
| US-20260085041-A1 | SALTS AND SOLID FORMS OF 4-HYDROXY-N,N-DIISOPROPYLTRYPTAMINE HEMI-GLUTARATE AND HEMI-SUCCINATE | SLC6A4, DLST, GRIN2D | HTR4 74/4885KCNH2 880/4885CYP3A4 858/4885 |
| US-20240165079-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | HTR4 10/4885KCNH2 2417/4885CYP3A4 3683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.